DataVXAdvanced Functional MaterialsPaper
journal article·2022-10Open access

Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection

Shuo Sun, Wei Gu, Haisi Wu, Qianqian Zhao, Shiyu Qian, Hong Xiao, Kun Yang, Jian Liu, Yu Jin, Chupeng Hu, Ye Gao, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen

Advanced Functional Materials· Volume 32· Issue 43
Publisher pageOpen full text
Source abstract

Abstract

Abstract Tumor recurrence remains the major cause of management failure after surgical resection of glioblastoma (GBM). Immunotherapy has the potential to effectively eradicate tumors and trigger immune memory to prevent tumor recurrence but not improve the outcomes of GBM patients. Here, an injectable, reactive oxygen species‐degradable therapeutic hydrogel (ADU‐AAV‐PD1@Gel), capable of sustained local release of soluble PD‐1 (sPD‐1) and stimulator of interferon gene (STING) agonist ADU‐S100 (ADU), is developed and applied in a GBM surgical resection model. Adeno‐associated virus serotype 9 is employed to stably express sPD‐1 blocking the PD‐1/PD‐L1 pathway. Concomitantly, the released ADU activates the STING pathway to improve tumor immunogenicity and response to therapy. This therapeutic hydrogel combined with radiotherapy (RT) effectively promotes sustained T cells infiltration and restores T cells effector function, which exhibits a robust antitumor immune response and significantly suppresses tumor growth. Moreover, ADU‐AAV‐PD1@Gel combined with RT treatment can also induce a long‐term immune memory to prevent GBM recurrence. As a result, ADU‐AAV‐PD1@Gel provides a novel strategy for effective radioimmunotherapy of GBM relapse post‐resection.
Source: crossref · Quality: baseline

Research context

Polymers

OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery The Affiliated Brain Hospital of Nanjing Medical University Nanjing 210029 P. R. China

Department of Immunology Gusu School Nanjing Medical University Nanjing 210029 P. R. China

Department of Neurosurgery The First Affiliated Hospital of Nanjing Medical University Nanjing 210029 P. R. China

Department of Pharmaceutics School of Pharmacy Nanjing Medical University Nanjing 210029 P. R. China

State Key Laboratory of Reproductive Medicine Department of Prenatal Diagnosis Women's Hospital of Nanjing Medical University Nanjing Maternity and Child Health Hospital Nanjing Medical University Nanjing 211166 P. R. China

Department of Immunology Key Laboratory of Human Functional Genomics of Jiangsu Province Gusu School Nanjing Medical University Nanjing 211166 P. R. China

Jiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing 210029 P. R. China

Department of Central Laboratory The Affiliated Huai'an No.1 People's Hospital Nanjing Medical University Huai'an 223300 P. R. China

Department of Emergency The First Affiliation Hospital of Xi'an Jiaotong University Xian 710061 P. R. China

Funding

National Natural Science Foundation of China

References (51)

Show source-provided references
1. 10.1038/s41571-018-0003-510.1038/s41571-018-0003-5 ↗
2. 10.1158/0008-5472.CAN-21-353410.1158/0008-5472.CAN-21-3534 ↗
3. 10.1038/nn.301910.1038/nn.3019 ↗
4. 10.1073/pnas.161539611310.1073/pnas.1615396113 ↗
5. 10.1038/s41568-019-0224-710.1038/s41568-019-0224-7 ↗
6. 10.1016/j.jconrel.2022.03.05010.1016/j.jconrel.2022.03.050 ↗
7. 10.1016/j.trecan.2022.04.01010.1016/j.trecan.2022.04.010 ↗
8. 10.1016/j.ccell.2017.02.00910.1016/j.ccell.2017.02.009 ↗
9. 10.1038/s41565-020-00843-710.1038/s41565-020-00843-7 ↗
10. 10.1038/s41591-018-0135-210.1038/s41591-018-0135-2 ↗
11. 10.1038/nature1443210.1038/nature14432 ↗
12. 10.1186/s12943-020-01247-w10.1186/s12943-020-01247-w ↗
13. 10.1038/s41551-020-0597-710.1038/s41551-020-0597-7 ↗
14. 10.1158/1078-0432.CCR-21-196310.1158/1078-0432.CCR-21-1963 ↗
15. Lee S. J. · J Immunother Cancer · 2021 · 9
16. 10.1146/annurev-biochem-040320-10162910.1146/annurev-biochem-040320-101629 ↗
17. 10.1126/scitranslmed.aaz660610.1126/scitranslmed.aaz6606 ↗
18. 10.1038/s41551-020-0597-710.1038/s41551-020-0597-7 ↗
19. 10.1126/sciadv.abc364610.1126/sciadv.abc3646 ↗
20. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
21. 10.1021/acsnano.7b0815210.1021/acsnano.7b08152 ↗
22. 10.1002/adfm.20200437710.1002/adfm.202004377 ↗
23. 10.1039/C5CC09239F10.1039/C5CC09239F ↗
24. 10.1016/j.biomaterials.2016.07.00210.1016/j.biomaterials.2016.07.002 ↗
25. 10.1021/ja303372u10.1021/ja303372u ↗
26. 10.3389/fimmu.2014.0025510.3389/fimmu.2014.00255 ↗
27. 10.1021/acs.nanolett.8b0272010.1021/acs.nanolett.8b02720 ↗
28. 10.1038/s41590-019-0561-410.1038/s41590-019-0561-4 ↗
29. 10.1038/s41467-020-20243-810.1038/s41467-020-20243-8 ↗
30. 10.1021/acsnano.0c1076410.1021/acsnano.0c10764 ↗
31. 10.1016/j.canlet.2020.12.04510.1016/j.canlet.2020.12.045 ↗
32. 10.1186/s12943-020-01250-110.1186/s12943-020-01250-1 ↗
33. 10.1136/jitc-2020-00190610.1136/jitc-2020-001906 ↗
34. 10.1016/S0140-6736(20)32598-810.1016/S0140-6736(20)32598-8 ↗
35. 10.1186/s13014-020-01678-110.1186/s13014-020-01678-1 ↗
36. Sheng H. · Journal for ImmunoTherapy of Cancer · 2019 · 8 · e340
37. 10.1158/1078-0432.CCR-17-357310.1158/1078-0432.CCR-17-3573 ↗
38. 10.1007/s11910-020-01042-610.1007/s11910-020-01042-6 ↗
39. 10.1200/JCO.21.0216610.1200/JCO.21.02166 ↗
40. Ehtesham M. · Cancer Res. · 2002 · 62 · 7170
41. 10.1186/s13046-022-02349-710.1186/s13046-022-02349-7 ↗
42. 10.1016/j.bioactmat.2021.12.02910.1016/j.bioactmat.2021.12.029 ↗
43. 10.1016/j.ctrv.2022.10236110.1016/j.ctrv.2022.102361 ↗
44. 10.1016/j.semcancer.2022.02.01110.1016/j.semcancer.2022.02.011 ↗
45. 10.1038/s41571-021-00518-910.1038/s41571-021-00518-9 ↗
46. 10.1038/s41590-019-0433-y10.1038/s41590-019-0433-y ↗
47. 10.1002/mco2.6110.1002/mco2.61 ↗
48. 10.1186/s12943-022-01513-z10.1186/s12943-022-01513-z ↗
49. 10.1158/2159-8290.CD-18-102010.1158/2159-8290.CD-18-1020 ↗
50. 10.1021/acsnano.0c0385010.1021/acsnano.0c03850 ↗
51. 10.1016/j.omto.2021.01.01010.1016/j.omto.2021.01.010 ↗